Perioperative antibiotics

Journal of Orthopaedic Research

Volumn 32, Issue SUPPL.1, 2014, Pages

  Hansen, Erik ^a   Belden, Katherine ^a   Silibovsky, Randi ^a   Vogt, Markus ^a   Arnold, William ^a   Bicanic, Goran ^a   Bini, Stefano ^a   Catani, Fabio ^a   Chen, Jiying ^a   Ghazavi, Mohammad ^a   Godefroy, Karine M ^a   Holham, Paul ^a   Hosseinzadeh, Hamid ^a   Kim II, Kang ^a   Kirketerp Moøller, Klaus ^a   Lidgren, Lars ^a   Lin, Jian Hao ^a   Lonner, Jess H ^a   Moore, Christopher C ^a   Papagelopoulos, Panayiotis ^a   Poultsides, Lazaros ^a   Randall, R Lor ^a   Roslund, Brian ^a   Saleh, Khalid ^a   Salmon, Julia V ^a   Schwarz, Edward ^a   Stuyck, Jose ^a   Dahl, Annette W ^a   Yamada, Koji ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFALOTIN; CEFATRIZINE; CEFAZOLIN; CEFOXITIN; CEFPROZIL; CEFTAROLINE; CEFUROXIME; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; CLOXACILLIN; FLUCLOXACILLIN; FUSIDIC ACID; GENTAMICIN; MEROPENEM; NAFCILIN; OXACILLINIS; PENICILLIN DERIVATIVE; PIPERACILLIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER; ALLOGRAFT; ANTIBIOTIC PROPHYLAXIS; ARTHROPLASTY; AUTOIMMUNE DISEASE; BACTERIAL COLONIZATION; BACTERIAL ENDOCARDITIS; BLOOD TRANSFUSION; DEBRIDEMENT; DIABETES MELLITUS; DOSE TIME EFFECT RELATION; ENTEROBACTERIACEAE; HEART VALVE PROSTHESIS; HIP ARTHROPLASTY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDWELLING CATHETER; INFECTIOUS ARTHRITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NOTE; OPERATION DURATION; OPERATIVE BLOOD LOSS; PENICILLIN ALLERGY; PERIPROSTHETIC JOINT INFECTION; PEROPERATIVE CARE; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURGICAL DRAINAGE; SURGICAL INFECTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TOURNIQUET; TREATMENT INDICATION; URINARY CATHETER; WOUND IRRIGATION; ANIMAL; ARTHRITIS, INFECTIOUS; BLADDER CATHETERIZATION; CONSENSUS DEVELOPMENT; CONTRAINDICATIONS; PROSTHESIS-RELATED INFECTIONS; REOPERATION; STANDARDS; URINARY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ARTHRITIS, INFECTIOUS; ARTHROPLASTY, REPLACEMENT; CEPHALOSPORINS; HEART VALVE PROSTHESIS; HUMANS; POSTOPERATIVE CARE; PROSTHESIS-RELATED INFECTIONS; REOPERATION; URINARY CATHETERIZATION; URINARY TRACT INFECTIONS; VANCOMYCIN;

EID: 84895815422     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22549     Document Type: Note

References (221)

1. Recommendations for the use of intravenous antibiotic prophylaxis in primary total joint arthroplasty. http://www.aaos.org/about/papers/advistmt/ 1027.asp. Accessed 2013.
2. Prokuski L. 2008. Prophylactic antibiotics in orthopaedic surgery. J Am Acad Orthop Surg 16:283-293.
3. Bratzler DW, Houck PM. 2004. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 38:1706-1715.
4. van Kasteren ME, Mannien J, Ott A, et al. 2007. Antibiotic prophylaxis and the risk of surgical site infections following total hip arthroplasty: timely administration is the most important factor. Clin Infect Dis 44:921-927.
5. Classen DC, Evans RS, Pestotnik SL, et al. 1992. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med 326:281-286.
6. Bratzler DW, Houck PM. 2005. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg 189:395-404.
7. Galandiuk S, Polk HC Jr., Jagelman DG, et al. 1989. Reemphasis of priorities in surgical antibiotic prophylaxis. Surg Gynecol Obstet 169:219-222.
8. Hawn MT, Richman JS, Vick CC, et al. 2013. Timing of surgical antibiotic prophylaxis and the risk of surgical site infection. JAMA Surg 148:649-657.
9. Weber WP, Marti WR, Zwahlen M, et al. 2008. The timing of surgical antimicrobial prophylaxis. Ann Surg 247:918-926.
10. Steinberg JP, Braun BI, Hellinger WC, et al. 2009. Timing of antimicrobial prophylaxis and the risk of surgical site infections: results from the Trial to Reduce Antimicrobial Prophylaxis Errors. Ann Surg 250:10-16.
11. Johnson DP. 1987. Antibiotic prophylaxis with cefuroxime in arthroplasty of the knee. J Bone Joint Surg Br 69:787-789.
12. Friedman RJ, Friedrich LV, White RL, et al. 1990. Antibiotic prophylaxis and tourniquet inflation in total knee arthroplasty. Clin Orthop Relat Res 260:17-23.
13. Soriano A, Bori G, Garcia-Ramiro S, et al. 2008. Timing of antibiotic prophylaxis for primary total knee arthroplasty performed during ischemia. Clin Infect Dis 46:1009-1014.
14. A WD, Robertsson O, Stefansdottir A, et al. Timing of preoperative antibiotics for knee arthroplasties: improving the routines in Sweden. Patient Saf Surg 5:22.
15. Neu HC. 1984. Cephalosporin antibiotics as applied in surgery of bones and joints. Clin Orthop Relat Res 190: 50-64.
16. Oishi CS, Carrion WV, Hoaglund FT. 1993. Use of parenteral prophylactic antibiotics in clean orthopaedic surgery. A review of the literature. Clin Orthop Relat Res 296:249-255.
17. Schurman DJ, Hirshman HP, Kajiyama G, et al. 1978. Cefazolin concentrations in bone and synovial fluid. J Bone Joint Surg Am 60:359-362.
18. Forse RA, Karam B, MacLean LD, et al. 1989. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 106:750-756, discussion 756-757.
19. Sodhi M, Axtell SS, Callahan J, et al. 2004. Is it safe to use carbapenems in patients with a history of allergy to penicillin? J Antimicrob Chemother 54:1155-1157.
20. Hill C, Flamant R, Mazas F, et al. 1981. Prophylactic cefazolin versus placebo in total hip replacement. Report of a multicentre double-blind randomised trial. Lancet 1:795-796.
21. Tyllianakis ME, Karageorgos A, Marangos MN, et al. 2010. Antibiotic prophylaxis in primary hip and knee arthroplasty: comparison between cefuroxime and two specific antistaphylococcal agents. J Arthroplasty 25:1078-1082.
22. Mauerhan DR, Nelson CL, Smith DL, et al. 1994. Prophylaxis against infection in total joint arthroplasty. One day of cefuroxime compared with three days of cefazolin. J Bone Joint Surg Am 76:39-45.
23. Stefansdottir A, Johansson D, Knutson K, et al. 2009. Microbiology of the infected knee arthroplasty: report from the Swedish Knee Arthroplasty Register on 426 surgically revised cases. Scand J Infect Dis 41:831-840.
24. Enzler MJ, Berbari E, Osmon DR. 2011. Antimicrobial prophylaxis in adults. Mayo Clin Proc 86:686-701.
25. Wilson W, Taubert KA, Gewitz M, et al. 2007. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 116:1736-1754.
26. Eagle KA, Guyton RA, Davidoff R, et al. 2004. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiolo-gy/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 110: e340-437.
27. Edwards FH, Engelman RM, Houck P, et al. 2006. The Society of Thoracic Surgeons Practice Guideline Series: antibiotic prophylaxis in cardiac surgery, part I: duration. Ann Thorac Surg 81:397-404.
28. Haydon TP, Presneill JJ, Robertson MS. 2010. Antibiotic prophylaxis for cardiac surgery in Australia. Med J Aust 192:141-143.
29. Mollan RA, Haddock M, Webb CH. 1992. Teicoplanin vs cephamandole for antimicrobial prophylaxis in prosthetic joint implant surgery: (preliminary results). Eur J Surg Suppl 567:19-21.
30. Lazzarini L, Pellizzer G, Stecca C, et al. 2001. Postoperative infections following total knee replacement: an epidemiological study. J Chemother 13:182-187.
31. Periti P, Pannuti F, Della Cuna GR, et al. 1991. Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: a comparative randomized multicenter study in metastatic breast carcinoma. Cancer Invest 9:249-255.
32. Periti P, Stringa G, Mini E. 1999. Comparative multicenter trial of teicoplanin versus cefazolin for antimicrobial prophylaxis in prosthetic joint implant surgery. Italian Study Group for Antimicrobial Prophylaxis in Orthopedic Surgery. Eur J Clin Microbiol Infect Dis 18:113-119.
33. Brogden RN, Peters DH. 1994. Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 47:823-854.
34. Wood MJ. 1996. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 37:209-222.
35. Wilson AP. 1988. Antibiotic prophylaxis in cardiac surgery. J Antimicrob Chemother 21:522-524.
36. Darley ES, MacGowan AP. 2004. Antibiotic treatment of gram-positive bone and joint infections. J Antimicrob Chemother 53:928-935.
37. Dash CH. 1975. Penicillin allergy and the cephalosporins. J Antimicrob Chemother 1:107-118.
38. Petz LD. 1978. Immunologic cross-reactivity between penicillins and cephalosporins: a review. J Infect Dis 137 (Suppl):S74-S79.
39. Kelkar PS, Li JT. 2001. Cephalosporin allergy. N Engl J Med 345:804-809.
40. Saxon A, Beall GN, Rohr AS, et al. 1987. Immediate hypersensitivity reactions to beta-lactam antibiotics. Ann Intern Med 107:204-215.
41. Pichichero ME. 2007. Use of selected cephalosporins in penicillin-Allergic patients: a paradigm shift. Diagn Microbiol Infect Dis 57(3 Suppl):13S-18S.
42. Pichichero ME, Casey JR. 2007. Safe use of selected cephalosporins in penicillin-Allergic patients: a meta-Analysis. Otolaryngol Head Neck Surg 136:340-347.
43. Audicana M, Bernaola G, Urrutia I, et al. 1994. Allergic reactions to betalactams: studies in a group of patients allergic to penicillin and evaluation of cross-reactivity with cephalosporin. Allergy 49:108-113.
44. Solensky R, Earl HS, Gruchalla RS. 2002. Lack of penicillin resensitization in patients with a history of penicillin allergy after receiving repeated penicillin courses. Arch Intern Med 162:822-826.
45. Campagna JD, Bond MC, Schabelman E, et al. 2012. The use of cephalosporins in penicillin-Allergic patients: a literature review. J Emerg Med 42:612-620.
46. DePestel DD, Benninger MS, Danziger L, et al. 2008. Cephalosporin use in treatment of patients with penicillin allergies. J Am Pharm Assoc (2003) 48:530-540.
47. Platt R. 1982. Adverse effects of third-generation cephalosporins. J Antimicrob Chemother 10:135-140.
48. Goodman EJ, Morgan MJ, Johnson PA, et al. 2001. Cephalosporins can be given to penicillin-Allergic patients who do not exhibit an anaphylactic response. J Clin Anesth 13:561-564.
49. Apter AJ, Kinman JL, Bilker WB, et al. 2006. Is there cross-reactivity between penicillins and cephalosporins? Am J Med 119:354.e1-359.e1.
50. Park MA, Koch CA, Klemawesch P, et al. 2010. Increased adverse drug reactions to cephalosporins in penicillin allergy patients with positive penicillin skin test. Int Arch Allergy Immunol 153:268-273.
51. Advisory statement. Recommendations for the use of intravenous antibiotic prophylaxis in primary total joint arthroplasty. http://www.aaos.org/about/ papers/advistmt/1027.asp. Accessed 2013.
52. Muto CA, Jernigan JA, Ostrowsky BE, et al. 2003. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 24:362-386.
53. Cantoni L, Glauser MP, Bille J. 1990. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother 34:2348-2353.
54. Patel M, Kumar RA, Stamm AM, et al. 2007. USA300 genotype community-Associated methicillin-resistant Staphylococcus aureus as a cause of surgical site infections. J Clin Microbiol 45:3431-3433.
55. Manian FA, Griesnauer S. 2008. Community-Associated methicillin-resistant Staphylococcus aureus (MRSA) is replacing traditional health care-Associated MRSA strains in surgical-site infections among inpatients. Clin Infect Dis 47:434-435.
56. Recommendations for preventing the spread of vancomycin resistance. 1995. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 44:1-13.
57. Hiramatsu K, Aritaka N, Hanaki H, et al. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
58. Michel M, Gutmann L. 1997. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Lancet 349:1901-1906.
59. Fulkerson E, Valle CJ, Wise B, et al. 2006. Antibiotic susceptibility of bacteria infecting total joint arthroplasty sites. J Bone Joint Surg Am 88:1231-1237.
60. UK Health protection agency. Surgical Site Infection surveillance service. Protocol for surveillance of surgical site infection. http://www.hpa.org/uk/we/HPAwebFile/HPAweb-C/1194947388966. Accessed 2013.
61. Meehan J, Jamali AA, Nguyen H. 2009. Prophylactic antibiotics in hip and knee arthroplasty. J Bone Joint Surg Am 91:2480-2490.
62. Wiesel BB, Esterhai JL. 2003. Prophylaxis of musculoskeletal infections. In: Calhoun JH, Mader J, editors. Musculosketal Infections. New York: Marcel Dekker; 115-129.
63. Merrer J, Desbouchages L, Serazin V, et al. 2006. Comparison of routine prophylaxis with vancomycin or cefazolin for femoral neck fracture surgery: microbiological and clinical outcomes. Infect Control Hosp Epidemiol 27:1366-1371.
64. Cranny G, Elliott R, Weatherly H, et al. 2008. A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery. Health Technol Assess 12: iii-iv, xi-xii, 1-147.
65. Bolon MK, Morlote M, Weber SG, et al. 2004. Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a metaanalysis. Clin Infect Dis 38:1357-1363.
66. Mangram AJ, Horan TC, Pearson ML, et al. 1999. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 20:250-278, quiz 279-280.
67. Tacconelli E, Cataldo MA, Albanese A, et al. 2008. Vancomycin versus cefazolin prophylaxis for cerebrospinal shunt placement in a hospital with a high prevalence of meticillin-resistant Staphylococcus aureus. J Hosp Infect 69:337-344.
68. Finkelstein R, Rabino G, Mashiah T, et al. 2002. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 123:326-332.
69. Garey KW, Lai D, Dao-Tran TK, et al. 2008. Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery. Antimicrob Agents Chemother 52:446-451.
70. Spelman D, Harrington G, Russo P, et al. 2002. Clinical, microbiological, and economic benefit of a change in antibiotic prophylaxis for cardiac surgery. Infect Control Hosp Epidemiol 23:402-404.
71. Smith EB, Wynne R, Joshi A, et al. 2012. Is it time to include vancomycin for routine perioperative antibiotic prophylaxis in total joint arthroplasty patients? J Arthroplasty 27:55-60.
72. Bull AL, Worth LJ, Richards MJ. 2012. Impact of vancomycin surgical antibiotic prophylaxis on the development of methicillin-sensitive staphylococcus aureus surgical site infections: report from Australian Surveillance Data (VICNISS). Ann Surg 256:1089-1092.
73. Miller LG, McKinnell JA, Vollmer ME, et al. 2011. Impact of methicillin-resistant Staphylococcus aureus prevalence among S. aureus isolates on surgical site infection risk after coronary artery bypass surgery. Infect Control Hosp Epidemiol 32:342-350.
74. Zanetti G, Giardina R, Platt R. 2001. Intraoperative redosing of cefazolin and risk for surgical site infection in cardiac surgery. Emerg Infect Dis 7:828-831.
75. Zanetti G, Goldie SJ, Platt R. 2001. Clinical consequences and cost of limiting use of vancomycin for perioperative prophylaxis: example of coronary artery bypass surgery. Emerg Infect Dis 7:820-827.
76. Muralidhar B, Anwar SM, Handa AI, et al. 2006. Prevalence of MRSA in emergency and elective patients admitted to a vascular surgical unit: implications for antibiotic prophylaxis. Eur J Vasc Endovasc Surg 32:402-407.
77. Gemmell CG, Edwards DI, Fraise AP, et al. 2006. Guidelines for the prophylaxis and treatment of methicillinresistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 57:589-608.
78. Elliott RA, Weatherly HL, Hawkins NS, et al. 2010. An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis? Eur J Health Econ 11:57-66.
79. Walsh EE, Greene L, Kirshner R. 2011. Sustained reduction in methicillin-resistant Staphylococcus aureus wound infections after cardiothoracic surgery. Arch Intern Med 171:68-73.
80. Dhadwal K, Al-Ruzzeh S, Athanasiou T, et al. 2007. Comparison of clinical and economic outcomes of two antibiotic prophylaxis regimens for sternal wound infection in high-risk patients following coronary artery bypass grafting surgery: a prospective randomised double-blind controlled trial. Heart 93:1126-1133.
81. Patrick S, James C, Ali A, et al. 2010. Vascular surgical antibiotic prophylaxis study (VSAPS). Vasc Endovascular Surg 44:521-528.
82. Sewick A, Makani A, Wu C, et al. 2012. Does dual antibiotic prophylaxis better prevent surgical site infections in total joint arthroplasty? Clin Orthop Relat Res 470:2702-2707.
83. Ritter MA, Barzilauskas CD, Faris PM, et al. 1989. Vancomycin prophylaxis and elective total joint arthroplasty. Orthopedics 12:1333-1336.
84. Cruess RL, Bickel WS, vonKessler KL. 1975. Infections in total hips secondary to a primary source elsewhere. Clin Orthop Relat Res 106:99-101.
85. Hall AJ. 1974. Late infection about a total knee prosthesis. Report of a case secondary to urinary tract infection. J Bone Joint Surg Br 56:144-147.
86. David TS, Vrahas MS. 2000. Perioperative lower urinary tract infections and deep sepsis in patients undergoing total joint arthroplasty. J Am Acad Orthop Surg 8:66-74.
87. Ritter MA, Fechtman RW. 1987. Urinary tract sequelae: possible influence on joint infections following total joint replacement. Orthopedics 10:467-469.
88. Wymenga AB, van Horn JR, Theeuwes A, et al. 1992. Perioperative factors associated with septic arthritis after arthroplasty. Prospective multicenter study of 362 knee and 2,651 hip operations. Acta Orthop Scand 63:665-671.
89. Glynn MK, Sheehan JM. 1984. The significance of asymptomatic bacteriuria in patients undergoing hip/knee arthroplasty. Clin Orthop Relat Res 151-154.
90. Waterhouse N, Beaumont AR, Murray K, et al. 1987. Urinary retention after total hip replacement. A prospective study. J Bone Joint Surg Br 69:64-66.
91. Walton JK, Robinson RG. 1982. An analysis of a male population having total hip replacement with regard to urological assessment and post-operative urinary retention. Br J Urol 54:519-521.
92. Drekonja DM, Rector TS, Cutting A, et al. 2013. Urinary tract infection in male veterans: treatment patterns and outcomes. JAMA Intern Med 173:62-68.
93. Irvine R, Johnson BL Jr., Amstutz HC. 1974. The relationship of genitourinary tract procedures and deep sepsis after total hip replacements. Surg Gynecol Obstet 139:701-706.
94. Garibaldi RA, Burke JP, Dickman ML, et al. 1974. Factors predisposing to bacteriuria during indwelling urethral catheterization. N Engl J Med 291:215-219.
95. Kunin CM, McCormack RC. 1966. Prevention of catheterinduced urinary-tract infections by sterile closed drainage. N Engl J Med 274:1155-1161.
96. Jerry GJ Jr., Rand JA, Ilstrup D. 1988. Old sepsis prior to total knee arthroplasty. Clin Orthop Relat Res 135-140.
97. Lee GC, Pagnano MW, Hanssen AD. 2002. Total knee arthroplasty after prior bone or joint sepsis about the knee. Clin Orthop Relat Res 226-231.
98. Larson AN, Hanssen AD, Cass JR. 2009. Does prior infection alter the outcome of TKA after tibial plateau fracture? Clin Orthop Relat Res 467:1793-1799.
99. Michelson JD, Lotke PA, Steinberg ME. 1988. Urinarybladder management after total joint-replacement surgery. N Engl J Med 319:321-326.
100. Martinez OV, Civetta JM, Anderson K, et al. 1986. Bacteriuria in the catheterized surgical intensive care patient. Crit Care Med 14:188-191.
101. Schaeffer AJ. 1986. Catheter-Associated bacteriuria. Urol Clin North Am 13:735-747.
102. Skelly JM, Guyatt GH, Kalbfleisch R, et al. 1992. Management of urinary retention after surgical repair of hip fracture. CMAJ 146:1185-1189.
103. Donovan TL, Gordon RO, Nagel DA. 1976. Urinary infections in total hip arthroplasty. Influences of prophylactic cephalosporins and catheterization. J Bone Joint Surg Am 58:1134-1137.
104. Fitzgerald RH Jr., Nolan DR, Ilstrup DM, et al. 1977. Deep wound sepsis following total hip arthroplasty. J Bone Joint Surg Am 59:847-855.
105. Surin VV, Sundholm K, Backman L. 1983. Infection after total hip replacement. With special reference to a discharge from the wound. J Bone Joint Surg Br 65:412-418.
106. Felippe WA, Werneck GL, Santoro-Lopes G. 2007. Surgical site infection among women discharged with a drain in situ after breast cancer surgery. World J Surg 31:2293-2299, discussion 2300-2291.
107. Lanier ST, Wang ED, Chen JJ, et al. 2010. The effect of acellular dermal matrix use on complication rates in tissue expander/implant breast reconstruction. Ann Plast Surg 64:674-678.
108. Sorensen AI, Sorensen TS. 1991. Bacterial growth on suction drain tips. Prospective study of 489 clean orthopedic operations. Acta Orthop Scand 62:451-454.
109. van den Brand IC, Castelein RM. 2001. Total joint arthroplasty and incidence of postoperative bacteriuria with an indwelling catheter or intermittent catheterization with one-dose antibiotic prophylaxis: a prospective randomized trial. J Arthroplasty 16:850-855.
110. Oishi CS, Williams VJ, Hanson PB, et al. 1995. Perioperative bladder management after primary total hip arthroplasty. J Arthroplasty 10:732-736.
111. Koulouvaris P, Sculco P, Finerty E, et al. 2009. Relationship between perioperative urinary tract infection and deep infection after joint arthroplasty. Clin Orthop Relat Res 467:1859-1867.
112. Brahmbhatt RD, Huebner M, Scow JS, et al. 2012. National practice patterns in preoperative and postoperative antibiotic prophylaxis in breast procedures requiring drains: survey of the American Society of Breast Surgeons. Ann Surg Oncol 19:3205-3211.
113. Phillips BT, Wang ED, Mirrer J, et al. 2011. Current practice among plastic surgeons of antibiotic prophylaxis and closed-suction drains in breast reconstruction: experience, evidence, and implications for postoperative care. Ann Plast Surg 66:460-465.
114. Turano A. 1992. New clinical data on the prophylaxis of infections in abdominal, gynecologic, and urologic surgery. Multicenter Study Group. Am J Surg 164(4A Suppl):16S-20S.
115. Niederhauser U, Vogt M, Vogt P, et al. 1997. Cardiac surgery in a high-risk group of patients: is prolonged postoperative antibiotic prophylaxis effective? J Thorac Cardiovasc Surg 114:162-168.
116. Wymenga AB, Hekster YA, Theeuwes A, et al. 1991. Antibiotic use after cefuroxime prophylaxis in hip and knee joint replacement. Clin Pharmacol Ther 50:215-220.
117. McDonald M, Grabsch E, Marshall C, et al. 1998. Singleversus multiple-dose antimicrobial prophylaxis for major surgery: a systematic review. Aust N Z J Surg 68:388-396.
118. Heydemann JS, Nelson CL. 1986. Short-term preventive antibiotics. Clin Orthop Relat Res 205:184-187.
119. Stone HH, Haney BB, Kolb LD, et al. 1979. Prophylactic and preventive antibiotic therapy: timing, duration and economics. Ann Surg 189:691-699.
120. Williams DN, Gustilo RB. 1984. The use of preventive antibiotics in orthopaedic surgery. Clin Orthop Relat Res 190:83-88.
121. Tang WM, Chiu KY, Ng TP, et al. 2003. Efficacy of a single dose of cefazolin as a prophylactic antibiotic in primary arthroplasty. J Arthroplasty 18:714-718.
122. Bengston S, Knutson K, Lidgren L. 1989. Treatment of infected knee arthroplasty. Clin Orthop Relat Res 245:173-178.
123. Sharma D, Douglas J, Coulter C, et al. 2008. Microbiology of infected arthroplasty: implications for empiric perioperative antibiotics. J Orthop Surg (Hong Kong) 16:339-342.
124. Nickinson RS, Board TN, Gambhir AK, et al. 2010. The microbiology of the infected knee arthroplasty. Int Orthop 34:505-510.
125. Peersman G, Laskin R, Davis J, et al. 2001. Infection in total knee replacement: a retrospective review of 6489 total knee replacements. Clin Orthop Relat Res 392:15-23.
126. Mont MA, Waldman BJ, Hungerford DS. 2000. Evaluation of preoperative cultures before second-stage reimplantation of a total knee prosthesis complicated by infection. A comparison-group study. J Bone Joint Surg Am 82-A:1552-1557.
127. Rafiq I, Gambhir AK, Wroblewski BM, et al. 2006. The microbiology of infected hip arthroplasty. Int Orthop 30: 532-535.
128. Al-Maiyah M, Hill D, Bajwa A, et al. 2005. Bacterial contaminants and antibiotic prophylaxis in total hip arthroplasty. J Bone Joint Surg Br 87:1256-1258.
129. Phillips JE, Crane TP, Noy M, et al. 2006. The incidence of deep prosthetic infections in a specialist orthopaedic hospital: a 15-year prospective survey. J Bone Joint Surg Br 88:943-948.
130. Tsukayama DT, Estrada R, Gustilo RB. 1996. Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections. J Bone Joint Surg Am 78:512-523.
131. Moran E, Masters S, Berendt AR, et al. 2007. Guiding empirical antibiotic therapy in orthopaedics: the microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention. J Infect 55:1-7.
132. Azzam K, McHale K, Austin M, et al. 2009. Outcome of a second two-stage reimplantation for periprosthetic knee infection. Clin Orthop Relat Res 467:1706-1714.
133. Kalra KP, Lin KK, Bozic KJ, et al. 2010. Repeat 2-stage revision for recurrent infection of total hip arthroplasty. J Arthroplasty 25:880-884.
134. Jamsen E, Stogiannidis I, Malmivaara A, et al. 2009. Outcome of prosthesis exchange for infected knee arthroplasty: the effect of treatment approach. Acta Orthop 80:67-77.
135. Kubista B, Hartzler RU, Wood CM, et al. 2012. Reinfection after two-stage revision for periprosthetic infection of total knee arthroplasty. Int Orthop 36:65-71.
136. Mortazavi SM, O'Neil JT, Zmistowski B, et al. 2012. Repeat 2-stage exchange for infected total hip arthroplasty: a viable option? J Arthroplasty 27:923.e1-926.e1.
137. Fletcher N, Sofianos D, Berkes MB, et al. 2007. Prevention of perioperative infection. J Bone Joint Surg Am 89:1605-1618.
138. Dellinger EP, Gross PA, Barrett TL, et al. 1994. Quality standard for antimicrobial prophylaxis in surgical procedures. The Infectious Diseases Society of America. Infect Control Hosp Epidemiol 15:182-188.
139. Scher KS. 1997. Studies on the duration of antibiotic administration for surgical prophylaxis. Am Surg 63:59-62.
140. Shapiro M, Munoz A, Tager IB, et al. 1982. Risk factors for infection at the operative site after abdominal or vaginal hysterectomy. N Engl J Med 307:1661-1666.
141. Polk HC Jr., Trachtenberg L, Finn MP. 1980. Antibiotic activity in surgical incisions. The basis of prophylaxis in selected operations. JAMA 244:1353-1354.
142. Ohge H, Takesue Y, Yokoyama T, et al. 1999. An additional dose of cefazolin for intraoperative prophylaxis. Surg Today 29:1233-1236.
143. Morita S, Nishisho I, Nomura T, et al. 2005. The significance of the intraoperative repeated dosing of antimicrobials for preventing surgical wound infection in colorectal surgery. Surg Today 35:732-738.
144. Swoboda SM, Merz C, Kostuik J, et al. 1996. Does intraoperative blood loss affect antibiotic serum and tissue concentrations? Arch Surg 131:1165-1171, discussion 1171-1172.
145. Markantonis SL, Kostopanagiotou G, Panidis D, et al. 2004. Effects of blood loss and fluid volume replacement on serum and tissue gentamicin concentrations during colorectal surgery. Clin Ther 26:271-281.
146. Klekamp JW, DiPersio D, Haas DW. 1999. No influence of large volume blood loss on serum vancomycin concentrations during orthopedic procedures. Acta Orthop Scand 70:47-50.
147. Meter JJ, Polly DW Jr., Brueckner RP, et al. 1996. Effect of intraoperative blood loss on the serum level of cefazolin in patients managed with total hip arthroplasty. A prospective, controlled study. J Bone Joint Surg Am 78:1201-1205.
148. Polly DW Jr., Meter JJ, Brueckner R, et al. 1996. The effect of intraoperative blood loss on serum cefazolin level in patients undergoing instrumented spinal fusion. A prospective, controlled study. Spine (Phila Pa 1976) 21:2363-2367.
149. Sanford JP, Moellering RC, Gilbert DN, editors. 2000. Sanford guide to antimicrobial therapy. 30th ed; Antimicrobial Therapy, Inc.
150. Wurtz R, Itokazu G, Rodvold K. 1997. Antimicrobial dosing in obese patients. Clin Infect Dis. 25:112-118.
151. Leader WG, Tsubaki T, Chandler MH. 1994. Creatinineclearance estimates for predicting gentamicin pharmacokinetic values in obese patients. Am J Hosp Pharm 51:2125-2130.
152. Janson B, Thursky K. 2012. Dosing of antibiotics in obesity. Curr Opin Infect Dis 25:634-649.
153. Begg EJ, Barclay ML, Duffull SB. 1995. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 39:605-609.
154. Truong J, Levkovich BJ, Padiglione AA. 2012. Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels. Intern Med J 42:23-29.
155. Ho VP, Nicolau DP, Dakin GF, et al. 2012. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect (Larchmt) 13:33-37.
156. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. 2009. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49:325-327.
157. Traynor AM, Nafziger AN, Bertino JS Jr. 1995. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 39:545-548.
158. van Kralingen S, Taks M, Diepstraten J, et al. 2011. Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. Eur J Clin Pharmacol 67:985-992.
159. Edmiston CE, Krepel C, Kelly H, et al. 2004. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels? Surgery 136:738-747.
160. Liu C. 2011. The bundled approach to MRSA surgical site infection prevention: is the whole greater than the sum of its parts?: comment on "Sustained reduction in methicillinresistant Staphylococcus aureus wound infections after cardiothoracic surgery". Arch Intern Med 171:73-74.
161. Pofahl WE, Goettler CE, Ramsey KM, et al. 2009. Active surveillance screening of MRSA and eradication of the carrier state decreases surgical-site infections caused by MRSA. J Am Coll Surg 208:981-986, discussion 986-988.
162. Wirganowicz PZ, Eckardt JJ, Dorey FJ, et al. 1999. Etiology and results of tumor endoprosthesis revision surgery in 64 patients. Clin Orthop Relat Res 358:64-74.
163. Safran MR, Kody MH, Namba RS, et al. 1994. 151 endoprosthetic reconstructions for patients with primary tumors involving bone. Contemp Orthop 29:15-25.
164. Malawer MM, Chou LB. 1995. Prosthetic survival and clinical results with use of large-segment replacements in the treatment of high-grade bone sarcomas. J Bone Joint Surg Am 77:1154-1165.
165. Capanna R, Morris HG, Campanacci D, et al. 1994. Modular uncemented prosthetic reconstruction after resection of tumours of the distal femur. J Bone Joint Surg Br 76:178-186.
166. Mittermayer F, Krepler P, Dominkus M, et al. 2001. Longterm followup of uncemented tumor endoprostheses for the lower extremity. Clin Orthop Relat Res 388:167-177.
167. Ghert M, Deheshi B, Holt G, et al. 2012. Prophylactic antibiotic regimens in tumour surgery (PARITY): protocol for a multicentre randomised controlled study. BMJ Open 2.
168. Jansen B, Rinck M, Wolbring P, et al. 1994. In vitro evaluation of the antimicrobial efficacy and biocompatibility of a silver-coated central venous catheter. J Biomater Appl 9:55-70.
169. Karchmer TB, Giannetta ET, Muto CA, et al. 2000. A randomized crossover study of silver-coated urinary catheters in hospitalized patients. Arch Intern Med 160:3294-3298.
170. Tsuchiya H, Shirai T, Nishida H. 2013. New implant technology: iodine-coating for infection control. Paper presented at: 26th European Musculoskeletal Oncology Society Meeting, Gothenburg, Sweden.
171. Tsuchiya H, Shirai T, Nishida H, et al. 2012. Innovative antimicrobial coating of titanium implants with iodine. J Orthop Sci 17:595-604.
172. Hardes J, von Eiff C, Streitbuerger A, et al. 2010. Reduction of periprosthetic infection with silver-coated megaprostheses in patients with bone sarcoma. J Surg Oncol 101:389-395.
173. Gosheger G, Hardes J, Ahrens H, et al. 2004. Silver-coated megaendoprostheses in a rabbit model-An analysis of the infection rate and toxicological side effects. Biomaterials 25:5547-5556.
174. Buttaro MA, Gimenez MI, Greco G, et al. 2005. High active local levels of vancomycin without nephrotoxicity released from impacted bone allografts in 20 revision hip arthroplasties. Acta Orthop 76:336-340.
175. Gosheger G, Goetze C, Hardes J, et al. 2008. The influence of the alloy of megaprostheses on infection rate. J Arthroplasty 23:916-920.
176. Witso E, Persen L, Benum P, et al. 2004. High local concentrations without systemic adverse effects after impaction of netilmicin-impregnated bone. Acta Orthop Scand 75:339-346.
177. Buttaro MA, Pusso R, Piccaluga F. 2005. Vancomycinsupplemented impacted bone allografts in infected hip arthroplasty. Two-stage revision results. J Bone Joint Surg Br 87:314-319.
178. Michalak KA, Khoo PP, Yates PJ, et al. 2006. Iontophoresed segmental allografts in revision arthroplasty for infection. J Bone Joint Surg Br 88:1430-1437.
179. Khoo PP, Michalak KA, Yates PJ, et al. 2006. Iontophoresis of antibiotics into segmental allografts. J Bone Joint Surg Br 88:1149-1157.
180. Winkler H, Stoiber A, Kaudela K, et al. 2008. One stage uncemented revision of infected total hip replacement using cancellous allograft bone impregnated with antibiotics. J Bone Joint Surg Br 90:1580-1584.
181. Buttaro MA, Guala AJ, Comba F, et al. 2010. Incidence of deep infection in aseptic revision THA using vancomycinimpregnated impacted bone allograft. Hip Int 20:535-541.
182. Witso E, Persen L, Loseth K, et al. 1999. Adsorption and release of antibiotics from morselized cancellous bone. In vitro studies of antibiotics. Acta Orthop Scand 70:298-304.
183. Buttaro MA, Gonzalez Della Valle AM, Pineiro L, et al. 2003. Incorporation of vancomycin-supplemented bone incorporation of vancomycin-supplemented bone allografts: radiographical, histopathological and immunohistochemical study in pigs. Acta Orthop Scand 74:505-513.
184. Witso E, Persen L, Loseth K, et al. 2000. Cancellous bone as an
185. Berbari EF, Hanssen AD, Duffy MC, et al. 1998. Risk factors for prosthetic joint infection: case-control study. Clin Infect Dis 27:1247-1254.
186. Yang K, Yeo SJ, Lee BP, et al. 2001. Total knee arthroplasty in diabetic patients: a study of 109 consecutive cases. J Arthroplasty 16:102-106.
187. Meding JB, Reddleman K, Keating ME, et al. 2003. Total knee replacement in patients with diabetes mellitus. Clin Orthop Relat Res 416:208-216.
188. Pedersen AB, Mehnert F, Johnsen SP, et al. 2010. Risk of revision of a total hip replacement in patients with diabetes mellitus: a population-based follow up study. J Bone Joint Surg Br 92:929-934.
189. Adams AL, Paxton EW, Wang JQ, et al. 2013. Surgical outcomes of total knee replacement according to diabetes status and glycemic control, 2001 to 2009. J Bone Joint Surg Am 95:481-487.
190. Haverkamp D, Klinkenbijl MN, Somford MP, et al. 2011. Obesity in total hip arthroplasty-does it really matter? A meta-Analysis. Acta Orthop 82:417-422.
191. Namba RS, Paxton L, Fithian DC, et al. 2005. Obesity and perioperative morbidity in total hip and total knee arthroplasty patients. J Arthroplasty 20:46-50.
192. Dowsey MM, Choong PF. 2008. Early outcomes and complications following joint arthroplasty in obese patients: a review of the published reports. ANZ J Surg 78:439-444.
193. Parvizi J, Sullivan TA, Pagnano MW, et al. 2003. Total joint arthroplasty in human immunodeficiency virus-positive patients: an alarming rate of early failure. J Arthroplasty 18:259-264.
194. Ragni MV, Crossett LS, Herndon JH. 1995. Postoperative infection following orthopaedic surgery in human immunodeficiency virus-infected hemophiliacs with CD4 counts
195. Habermann B, Eberhardt C, Kurth AA. 2008. Total joint replacement in HIV positive patients. J Infect 57:41-46.
196. Wang TI, Chen CF, Chen WM, et al. 2012. Joint replacement in human immunodeficiency virus-infected patients. J Chin Med Assoc 75:595-599.
197. Unger AS, Kessler CM, Lewis RJ. 1995. Total knee arthroplasty in human immunodeficiency virus-infected hemophiliacs. J Arthroplasty 10:448-452.
198. Silva M, Luck JV Jr. 2005. Long-term results of primary total knee replacement in patients with hemophilia. J Bone Joint Surg Am 87:85-91.
199. Rodriguez-Merchan EC. 2007. Total knee replacement in haemophilic arthropathy. J Bone Joint Surg Br 89:186-188.
200. Shaarani SR, Collins D, O'Byrne JM. 2012. The need for guidelines in asplenic patients undergoing total joint arthroplasty: a case report. Case Rep Orthop 2012: 147042.
201. McCleery MA, Leach WJ, Norwood T. 2010. Rates of infection and revision in patients with renal disease undergoing total knee replacement in Scotland. J Bone Joint Surg Br 92:1535-1539.
202. Lieberman JR, Fuchs MD, Haas SB, et al. 1995. Hip arthroplasty in patients with chronic renal failure. J Arthroplasty 10:191-195.
203. Sakalkale DP, Hozack WJ, Rothman RH. 1999. Total hip arthroplasty in patients on long-term renal dialysis. J Arthroplasty 14:571-575.
204. Li WC, Shih CH, Ueng SW, et al. 2010. Uncemented total hip arthroplasty in chronic hemodialysis patients. Acta Orthop 81:178-182.
205. Nagoya S, Nagao M, Takada J, et al. 2005. Efficacy of cementless total hip arthroplasty in patients on long-term hemodialysis. J Arthroplasty 20:66-71.
206. Pour AE, Matar WY, Jafari SM, et al. 2011. Total joint arthroplasty in patients with hepatitis C. J Bone Joint Surg Am 93:1448-1454.
207. Orozco F, Post ZD, Baxi O, et al. 2014. Fibrosis in hepatitis C patients predicts complications after elective total joint arthroplasty. J Arthroplasty 29:7-10.
208. Vergidis P, Lesnick TG, Kremers WK, et al. 2012. Prosthetic joint infection in solid organ transplant recipients: a retrospective case-control study. Transpl Infect Dis 14:380-386.
209. Tannenbaum DA, Matthews LS, Grady-Benson JC. 1997. Infection around joint replacements in patients who have a renal or liver transplantation. J Bone Joint Surg Am 79:36-43.
210. Mortazavi SM, Molligan J, Austin MS, et al. 2011. Failure following revision total knee arthroplasty: infection is the major cause. Int Orthop 35:1157-1164.
211. Poss R, Thornhill TS, Ewald FC, et al. 1984. Factors influencing the incidence and outcome of infection following total joint arthroplasty. Clin Orthop Relat Res 182:117-126.
212. Sierra RJ, Cooney WPt, Pagnano MW, et al. 2004. Reoperations after 3200 revision TKAs: rates, etiology, and lessons learned. Clin Orthop Relat Res 425:200-206.
213. Liu C, Kakis A, Nichols A, et al. 2014. Targeted Use of Vancomycin as Perioperative Prophylaxis Reduces Periprosthetic Joint Infection in Revision TKA. Clin Orthop Relat Res 472:227-231.
214. Cuzon G, Naas T, Demachy MC, et al. 2008. Plasmidmediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece. Antimicrob Agents Chemother 52:796-797.
215. Nordmann P, Cuzon G, Naas T. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 9:228-236.
216. Queenan AM, Bush K. 2007. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 20:440-458, table of contents.
217. Schwaber MJ, Carmeli Y. 2008. Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA 300:2911-2913.
218. Bratu S, Landman D, Haag R, et al. 2005. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 165:1430-1435.
219. Marchaim D, Navon-Venezia S, Schwaber MJ, et al. 2008. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother 52:1413-1418.
220. de Smet AM, Kluytmans JA, Cooper BS, et al. 2009. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 360:20-31.
221. Perez F, Pultz MJ, Endimiani A, et al. 2011. Effect of antibiotic treatment on establishment and elimination of intestinal colonization by KPC-producing Klebsiella pneumoniae in mice. Antimicrob Agents Chemother 55:2585-2589.